What does Dr. Helena Maes, inwendige ziekten-hematologie do?

Dr. Helena Maes, inwendige ziekten-hematologie is a specialist medical practice in Keerbergen. Private Limited, started on 16 September 2016, 1 establishment.

What is the address of Dr. Helena Maes, inwendige ziekten-hematologie?

The registered office of Dr. Helena Maes, inwendige ziekten-hematologie is located at Raambeekweg 19, 3140 Keerbergen.

Is Dr. Helena Maes, inwendige ziekten-hematologie still active?

Yes. According to the CBE (18 September 2026) Dr. Helena Maes, inwendige ziekten-hematologie is active, legal situation “Normale toestand”, started on 16 September 2016.

Is Dr. Helena Maes, inwendige ziekten-hematologie registered on Peppol?

Yes, Dr. Helena Maes, inwendige ziekten-hematologie is registered on the Peppol network with ID 0208:0662643424.

What is the enterprise number of Dr. Helena Maes, inwendige ziekten-hematologie?

The enterprise number of Dr. Helena Maes, inwendige ziekten-hematologie is BE0662643424.

Who are the directors of Dr. Helena Maes, inwendige ziekten-hematologie?

According to the 2025 annual accounts, the directors of Dr. Helena Maes, inwendige ziekten-hematologie are: Klaas Beckers, Helena Maes.

Is Dr. Helena Maes, inwendige ziekten-hematologie a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 16 September 2016; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did Dr. Helena Maes, inwendige ziekten-hematologie make in 2025?

Dr. Helena Maes, inwendige ziekten-hematologie posted a profit after taxes of € 158,748 in financial year 2025.

What is the revenue of Dr. Helena Maes, inwendige ziekten-hematologie?

As a small company, Dr. Helena Maes, inwendige ziekten-hematologie is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 240,122.

Dr. Helena Maes, inwendige ziekten-hematologie (Private Limited)

Q: When was Dr. Helena Maes, inwendige ziekten-hematologie founded?

Dr. Helena Maes, inwendige ziekten-hematologie was founded on 16 September 2016.

Dossier Dr. Helena Maes, inwendige ziekten-hematologie, printed on 18 September 2026 from databakkes.be/en/0662643424/dr-helena-maes-inwendige-ziekten-hematologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dr. Helena Maes, inwendige ziekten-hematologie from Keerbergen, company number BE0662643424, closed financial year 2025 with a result of € 158,748 after tax. For that financial year Dr. Helena Maes, inwendige ziekten-hematologie recorded a gross margin of € 240,122 and equity of € 29,208. Compared with financial year 2024, the result moved from € 160,982 to € 158,748. The company is profitable. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.

What it is worth Growing

€ 29,208

▲ 33% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 158,748

▼ 1% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 136,596

▲ 33% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 151,459 paid out

95 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 53,440

▼ 35% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 1 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 22,431

▼ 42% vs 2024

€ 15,390 is repaid this year. At this pace the long-term loan is gone in ≈ 1 years.

Owed to suppliers

€ 997

▼ 75% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 5,103

▲ 4% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 177,643 Gross margin 2022: € 177,643 First fiscal year in the series	€ 185,383 Gross margin 2023: € 185,383 ▲ 4% vs 2022 (€ 177,643) Favourable step	€ 243,480 Gross margin 2024: € 243,480 ▲ 31% vs 2023 (€ 185,383) Favourable step	€ 240,122 Gross margin 2025: € 240,122 ▼ 1% vs 2024 (€ 243,480) Unfavourable step	▼ 1%
Profit after taxes	€ 123,903 Profit after taxes 2022: € 123,903 First fiscal year in the series	€ 124,390 Profit after taxes 2023: € 124,390 Unchanged (€ 123,903) Favourable step	€ 160,982 Profit after taxes 2024: € 160,982 ▲ 29% vs 2023 (€ 124,390) Favourable step	€ 158,748 Profit after taxes 2025: € 158,748 ▼ 1% vs 2024 (€ 160,982) Unfavourable step	▼ 1%
Equity	€ 20,547 Equity 2022: € 20,547 First fiscal year in the series	€ 20,937 Equity 2023: € 20,937 ▲ 2% vs 2022 (€ 20,547) Favourable step	€ 21,919 Equity 2024: € 21,919 ▲ 5% vs 2023 (€ 20,937) Favourable step	€ 29,208 Equity 2025: € 29,208 ▲ 33% vs 2024 (€ 21,919) Favourable step	▲ 33%
Total debts	€ 199,051 Total debts 2022: € 199,051 First fiscal year in the series	€ 187,779 Total debts 2023: € 187,779 ▼ 6% vs 2022 (€ 199,051) Favourable step	€ 215,164 Total debts 2024: € 215,164 ▲ 15% vs 2023 (€ 187,779) Unfavourable step	€ 191,119 Total debts 2025: € 191,119 ▼ 11% vs 2024 (€ 215,164) Favourable step	▼ 11%
Cash	€ 92,641 Cash 2022: € 92,641 First fiscal year in the series	€ 110,225 Cash 2023: € 110,225 ▲ 19% vs 2022 (€ 92,641) Favourable step	€ 102,899 Cash 2024: € 102,899 ▼ 7% vs 2023 (€ 110,225) Unfavourable step	€ 136,596 Cash 2025: € 136,596 ▲ 33% vs 2024 (€ 102,899) Favourable step	▲ 33%
Retained profit	€ 1,947 Retained profit 2022: € 1,947 First fiscal year in the series	€ 2,337 Retained profit 2023: € 2,337 ▲ 20% vs 2022 (€ 1,947) Favourable step	€ 3,319 Retained profit 2024: € 3,319 ▲ 42% vs 2023 (€ 2,337) Favourable step	€ 10,608 Retained profit 2025: € 10,608 ▲ 220% vs 2024 (€ 3,319) Favourable step	▲ 220%
Dividend	€ 124,000 Dividend 2022: € 124,000 First fiscal year in the series	€ 124,000 Dividend 2023: € 124,000 Unchanged (€ 124,000) Unchanged	€ 160,000 Dividend 2024: € 160,000 ▲ 29% vs 2023 (€ 124,000) Unchanged	€ 151,459 Dividend 2025: € 151,459 ▼ 5% vs 2024 (€ 160,000) Unchanged	▼ 5%
Bank debt	€ 69,809 Bank debt 2022: € 69,809 First fiscal year in the series	€ 54,155 Bank debt 2023: € 54,155 ▼ 22% vs 2022 (€ 69,809) Favourable step	€ 38,363 Bank debt 2024: € 38,363 ▼ 29% vs 2023 (€ 54,155) Favourable step	€ 22,431 Bank debt 2025: € 22,431 ▼ 42% vs 2024 (€ 38,363) Favourable step	▼ 42%
Balance sheet total	€ 219,598 Balance sheet total 2022: € 219,598 First fiscal year in the series	€ 208,716 Balance sheet total 2023: € 208,716 ▼ 5% vs 2022 (€ 219,598) Unchanged	€ 237,083 Balance sheet total 2024: € 237,083 ▲ 14% vs 2023 (€ 208,716) Unchanged	€ 220,327 Balance sheet total 2025: € 220,327 ▼ 7% vs 2024 (€ 237,083) Unchanged	▼ 7%

Key figures of Dr. Helena Maes, inwendige ziekten-hematologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Helena Maes, inwendige ziekten-hematologie?

What happened at Dr. Helena Maes, inwendige ziekten-hematologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 30, 2026 New annual accounts for financial year 2025: profit of € 158,748 (▼ 1% vs 2024). Source: NBB ↗
2023 Klaas Beckers became a director. NBB
Sep 16, 2016 New establishment in Keerbergen. KBO
Sep 16, 2016 Start of the company according to the CBE. KBO
2016 Helena Maes became a director. NBB

In short

From € 123,903 profit in 2022 to € 158,748 profit in 2025.

Paid € 168,527 in corporate taxes since 2022.

Best year ever: 2024, with € 160,982 profit.

Paid out € 559,459 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Dr. Helena Maes, inwendige ziekten-hematologie? We notify you, reason included.

Follow Dr. Helena Maes, inwendige ziekten-hematologie

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Klaas Beckers Helena Maes

Dr. Helena Maes, inwendige ziekten-hematologie

Behind Dr. Helena Maes, inwendige ziekten-hematologie are Klaas Beckers and Helena Maes.

See the full network in the app

Directors

According to the 2025 annual accounts

Klaas Beckers

Director

since 2023

Helena Maes

Director

since 2016

Establishments

Establishment units

Physical locations of this company

Registered office

Raambeekweg 19

3140 Keerbergen

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0662.643.424
VAT number: BE 0662.643.424
Registered office: Raambeekweg 19, 3140 Keerbergen
Names & denominations: Dr. Helena Maes, inwendige ziekten-hematologie
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 16 September 2016
Peppol: Active · Active since 16 May 2025
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗